Mikamo H, Kawazoe K, Izumi K, Watanabe K, Ueno K, Tamaya T
Department of Obstetrics and Gynecology, University of Gifu, School of Medicine, Japan.
Chemotherapy. 1997 Jan-Feb;43(1):60-8. doi: 10.1159/000239537.
The bacterial epidemiology of bacterial vaginosis (BV) and the efficacy of vaginal or oral treatment of BV with clindamycin (CLDM) were investigated. The epidemiology of BV was investigated in 100 symptomatic women before CLDM therapy. Two groups consisting of 50 patients each with the diagnosis of symptomatic BV were treated with either oral administration of 450 mg CLDM three times daily or 2% CLDM phosphate in vaginal cream (self-made) 5 g once a day, for 7 days. There was no significant differences in efficacy among vaginal and oral therapies with CLDM. Vulvovaginal irritation occurred in 3 patients orally treated and in 1 patient vaginally treated. Gastrointestinal disturbances were observed in 4 orally treated patients. A slight abnormal elevation of the glutamine-oxaloacetic transaminase level was also found in 1 patient orally treated. Since there were no statistically significant differences in efficacy rates between vaginal and oral CLDM treatments, we favor vaginal treatment of BV, based on less adverse effects.
对细菌性阴道病（BV）的细菌流行病学以及克林霉素（CLDM）阴道或口服治疗BV的疗效进行了研究。在CLDM治疗前，对100名有症状的女性进行了BV的流行病学调查。将两组各50例诊断为有症状BV的患者，分别采用每日3次口服450 mg CLDM或每天1次阴道使用5 g自制的2%克林霉素磷酸酯乳膏进行治疗，疗程为7天。CLDM阴道和口服治疗的疗效无显著差异。口服治疗的患者中有3例出现外阴阴道刺激，阴道治疗的患者中有1例出现该症状。口服治疗的患者中有4例出现胃肠道不适。口服治疗的1例患者还发现谷草转氨酶水平略有异常升高。由于CLDM阴道和口服治疗的有效率无统计学显著差异，基于不良反应较少，我们倾向于采用阴道治疗BV。
